File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2147/OPTH.S80500
- Scopus: eid_2-s2.0-84937709345
- WOS: WOS:000366356900002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study
Title | Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study |
---|---|
Authors | |
Keywords | Diabetic macular edema |
Issue Date | 2015 |
Citation | Clinical Ophthalmology, 2015, v. 9, p. 1255-1268 How to Cite? |
Abstract | © 2015 Lam et al.Background: The purpose of this study was to evaluate the real-world use, efficacy, and safety of one or more dexamethasone intravitreal implant(s) 0.7 mg (DEX implant) in patients with macular edema (ME). Methods: This was a retrospective cohort study of patients with ME secondary to retinal disease treated at ten Canadian retina practices, including one uveitis center. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), glaucoma and cataract surgery, and safety data were collected from the medical charts of patients with ≥3 months of follow-up after the initial DEX implant.Results: One hundred and one patient charts yielded data on 120 study eyes, including diagnoses of diabetic ME (DME) (n=34), retinal vein occlusion (RVO, n=30; branch in 19 and central in 11), and uveitis (n=23). Patients had a mean age of 60.9 years, and 73.3% of the study eyes had ME for a duration of ≥12 months prior to DEX implant injection(s). Baseline mean (± standard error) BCVA was 0.63±0.03 logMAR (20/86 Snellen equivalents) and mean CRT was 474.4±18.2 μm. The mean number of DEX implant injections was 1.7±0.1 in all study eyes; 44.2% of eyes had repeat DEX implant injections (reinjection interval 2.3–4.9 months). The greatest mean peak changes in BCVA lines of vision occurred in study eyes with uveitis (3.3±0.6, P<0.0001), followed by RVO (1.3±0.5, P<0.01) and DME (0.7±0.5, P>0.05). Significant decreases in CRT were observed: -255.6±43.6 µm for uveitis, -190.9±23.5 µm for DME, and -160.7±39.6 µm for RVO (P<0.0001 for all cohorts). IOP increases of ≥10 mmHg occurred in 20.6%, 24.1%, and 22.7% of DME, RVO, and uveitis study eyes, respectively. IOP-lowering medication was initiated in 29.4%, 16.7%, and 8.7% of DME, RVO, and uveitis study eyes, respectively. Glaucoma surgery was performed in 1.7% of all study eyes and cataract surgery in 29.8% of all phakic study eyes receiving DEX implant(s). onclusion: DEX implant(s) alone or combined with other treatments and/or procedures resulted in functional and anatomic improvements in long-standing ME associated with retinal disease. |
Persistent Identifier | http://hdl.handle.net/10722/228223 |
ISSN | 2023 SCImago Journal Rankings: 0.911 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, Wai Ching | - |
dc.contributor.author | Albiani, David A. | - |
dc.contributor.author | Yoganathan, Pradeepa | - |
dc.contributor.author | Chen, John Chanchiang | - |
dc.contributor.author | Kherani, Amin | - |
dc.contributor.author | Maberley, David A L | - |
dc.contributor.author | Oliver, Alejandro | - |
dc.contributor.author | Rabinovitch, Theodore | - |
dc.contributor.author | Sheidow, Thomas G. | - |
dc.contributor.author | Tourville, Eric | - |
dc.contributor.author | Wittenberg, Leah A. | - |
dc.contributor.author | Sigouin, Chris | - |
dc.contributor.author | Baptiste, Darryl C. | - |
dc.date.accessioned | 2016-08-01T06:45:30Z | - |
dc.date.available | 2016-08-01T06:45:30Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Clinical Ophthalmology, 2015, v. 9, p. 1255-1268 | - |
dc.identifier.issn | 1177-5467 | - |
dc.identifier.uri | http://hdl.handle.net/10722/228223 | - |
dc.description.abstract | © 2015 Lam et al.Background: The purpose of this study was to evaluate the real-world use, efficacy, and safety of one or more dexamethasone intravitreal implant(s) 0.7 mg (DEX implant) in patients with macular edema (ME). Methods: This was a retrospective cohort study of patients with ME secondary to retinal disease treated at ten Canadian retina practices, including one uveitis center. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), glaucoma and cataract surgery, and safety data were collected from the medical charts of patients with ≥3 months of follow-up after the initial DEX implant.Results: One hundred and one patient charts yielded data on 120 study eyes, including diagnoses of diabetic ME (DME) (n=34), retinal vein occlusion (RVO, n=30; branch in 19 and central in 11), and uveitis (n=23). Patients had a mean age of 60.9 years, and 73.3% of the study eyes had ME for a duration of ≥12 months prior to DEX implant injection(s). Baseline mean (± standard error) BCVA was 0.63±0.03 logMAR (20/86 Snellen equivalents) and mean CRT was 474.4±18.2 μm. The mean number of DEX implant injections was 1.7±0.1 in all study eyes; 44.2% of eyes had repeat DEX implant injections (reinjection interval 2.3–4.9 months). The greatest mean peak changes in BCVA lines of vision occurred in study eyes with uveitis (3.3±0.6, P<0.0001), followed by RVO (1.3±0.5, P<0.01) and DME (0.7±0.5, P>0.05). Significant decreases in CRT were observed: -255.6±43.6 µm for uveitis, -190.9±23.5 µm for DME, and -160.7±39.6 µm for RVO (P<0.0001 for all cohorts). IOP increases of ≥10 mmHg occurred in 20.6%, 24.1%, and 22.7% of DME, RVO, and uveitis study eyes, respectively. IOP-lowering medication was initiated in 29.4%, 16.7%, and 8.7% of DME, RVO, and uveitis study eyes, respectively. Glaucoma surgery was performed in 1.7% of all study eyes and cataract surgery in 29.8% of all phakic study eyes receiving DEX implant(s). onclusion: DEX implant(s) alone or combined with other treatments and/or procedures resulted in functional and anatomic improvements in long-standing ME associated with retinal disease. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Ophthalmology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Diabetic macular edema | - |
dc.title | Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.2147/OPTH.S80500 | - |
dc.identifier.scopus | eid_2-s2.0-84937709345 | - |
dc.identifier.volume | 9 | - |
dc.identifier.spage | 1255 | - |
dc.identifier.epage | 1268 | - |
dc.identifier.eissn | 1177-5483 | - |
dc.identifier.isi | WOS:000366356900002 | - |
dc.identifier.issnl | 1177-5467 | - |